Abstract: The present application discloses a temperature-controlled cup, comprising: an outer container; an inner container, which is removably accommodated within the outer container; at least two medium holders, which are removably accommodated within the outer container and positioned between the outer container and the inner container, each medium holder is provided with a storage space, the at least two medium holders are stacked up and down; and temperature-regulating medium, accommodated within the storage space, each storage space containing the temperature-regulating medium.

Abstract: A squeeze prevention bracket is provided. The squeeze prevention bracket includes a side wall and a top wall; the side wall and the top wall are enclosed to form an accommodating space configured to accommodate a food packaging bag; a first opening and a second opening are provided in the top wall; the first opening is at least divided into a first section and a second section; the first section and the second section are arranged towards an edge region of the top wall along a middle region of the top wall in sequence; a width of the second section is greater than a width of the first section; the second section is configured to arrange a connection port of the food packaging bag in a penetrating manner and slide the connection port into the first section; the first section is configured to be clamped with the connection port.

Abstract: Disclosed is a retractable gate fence, referring to the technical field of gate fence. The retractable gate fence includes a spool and a pulling cloth, one end of the pulling cloth is connected to the spool. The pulling cloth has a first state that is wound onto the spool and a second state that is unfolded from the spool, and the pulling cloth is provided with a plurality of reinforcing strips at intervals.

Abstract: A lighting device (10) comprises an elongate arrangement of LEDs (14) with outer rows (r1, r2) of LEDs extending along the length direction, and at least one inner row (r3) of LEDs between the outer rows (r1, r2) of LEDs. The pitch (p1) of the LEDs of the inner row (r3) is greater than the pitch (p2) of the LEDs along the first and second outer rows (r1, r2). Thus, the spottiness of the outer rows (r1, r2) is reduced by having a smaller pitch.

Abstract: A cluster management method includes starting an operating system of a network device and feeding back a startup result of an operating system. The cluster management system sends the startup indication to the computing device to control to start the computing device and the operating system of the network device included in the computing device, and the computing device feeds back the startup result.

Abstract: A battery detection system includes a battery assembly and an electronic device. The battery assembly includes a first connector and a detection module connected to the first connector. The electronic device includes a second connector and a control module connected to the second connector. When the first connector is connected to the second connector, the detection module is configured to output first identification information to the electronic device through the first connector. When the second connector receives the first identification information, the control module confirms that the battery assembly is in a connected state. After the first connector is disconnected from the second connector, the detection module generates and outputs second identification information. When information received by the second connector changes from the first identification information to the second identification information, the control module confirms that the battery assembly is disconnected.

Abstract: The invention provides a lighting device (1200) comprising (i) a light generating device (100), (ii) an air ionizer device (500), (iii) an airflow device (600), and a front part (750), wherein: (A) the lighting device (1200) comprises one or more first openings (710) and one or more second openings (720); wherein the front part (750) comprises the one or more second openings (720); (B) wherein the light generating device (100) is configured to generate device light (101); wherein the front part (750) comprises a first optical diffusor element (1151), wherein the light generating device (100) is configured upstream of the first optical diffusor element (1151), and wherein the first optical diffusor element (1151) is configured to transmit at least part of the device light (101); (C) the air ionizer device (500) is configured to generate in an operational mode charged particles at an electrode (1510); and (D) the airflow device (600) is configured to generate in the operational mode an airflow (1610) entraining

Abstract: The invention provides a device (1200) comprising (i) a light generating device (100), (ii) an air ionizer device (500), and (iii) an airflow device (600), wherein: (A) the device (1200) comprises one or more first openings (710) and a front part (750) comprising one or more second openings (720); (B) the air ionizer device (500) is configured to generate in an operational mode positively charged particles at a first electrode (510) and negatively charged particles at a second electrode (520); (C) the airflow device (600) is configured to generate in the operational mode a first airflow (610) entraining the positively charged particles and a second airflow (620) entraining the negatively charged particles; wherein the one or more first openings (710) are configured upstream of the airflow device (600) and the electrodes (510,520); wherein a first part (721) of the one or more second openings (720) is configured downstream of the airflow device (600) and the first electrode (510), and a second part (722) of th

Abstract: A long-distance high-voltage cable fault degree detection method. A cable fault positioning curve is obtained by using a frequency-domain reflection method, and a cable fault positioning compensation curve is determined by means of theoretical calculation in combination with the parameters of a frequency-domain incident signal, cable structure parameters, and characteristic parameters of each layer of materials of the field test; furthermore, a cable fault diagnosis curve is determined on the basis of the cable fault positioning curve and the cable fault positioning compensation curve, the severity of the fault is determined by means of the amplitude of a peak point of the cable fault diagnosis curve, and the accuracy of long-distance high-voltage cable fault degree diagnosis is effectively improved.

Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a combination of genes and their corresponding proteins. In several embodiments, one edit is to reduce expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR and at least two additional gene edits to enhance the cytotoxicity and/or persistence of the resulting cells. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.

Abstract: A nanonetwork with controlled chirality prepared via self-assembly of triblock terpolymers, wherein each of the triblock terpolymers includes a first block, a second block and a third block. The first block is connected to the second block, and the third block is connected to the second block. The first block, the second block and the third block are incompatible. The third block has a homochiral characteristic, and a chirality of the nanonetwork with controlled chirality is determined by the homochiral characteristic.

Abstract: An example of a method includes providing a substrate with an exposed surface comprising a first chemical group, wherein the providing optionally comprises modifying the exposed surface of the substrate to incorporate the first chemical group; reacting the first chemical group with a first reactive group of a functionalized polymer molecule to form a functionalized polymer coating layer covalently bound to the exposed surface of the substrate; grafting a primer to the functionalized polymer coating layer by reacting the primer with a second reactive group of the functionalized polymer coating layer; and forming a water-soluble protective coating on the primer and the functionalized polymer coating layer. Examples of flow cells incorporating examples of the water-soluble protective coating are also disclosed herein.

Abstract: The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PR.MTS (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3 S,SR)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 20 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 20 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.

Abstract: Systems and methods for characterizing biological specimens, which may involve identifying a cell type or state corresponding to a disease or health condition of a subject. A biological specimen is subjected to electromagnetic radiation for spectroscopic analysis such as Surface Enhanced Raman Spectroscopy (SERS) to determine the relative abundance of proteins or amino acids in the cells, which is used in a comparison to previously stored relative abundance data of a database to automatically identifies at least one of cell type and/or cell state of the cells (or the disease/health state of the subject with the disease state including the possibility of virus infection, or drug susceptibility of a subject to bacteria or fungus). The method may also be employed with biological entities or cellular structures such as exosomes and even protein or nucleic acid fragments to determine disease states or health states of the subject.

Abstract: An example of a method includes providing a substrate with an exposed surface comprising a first chemical group, wherein the providing optionally comprises modifying the exposed surface of the substrate to incorporate the first chemical group; reacting the first chemical group with a first reactive group of a functionalized polymer molecule to form a functionalized polymer coating layer covalently bound to the exposed surface of the substrate; grafting a primer to the functionalized polymer coating layer by reacting the primer with a second reactive group of the functionalized polymer coating layer; and forming a water-soluble protective coating on the primer and the functionalized polymer coating layer. Examples of flow cells incorporating examples of the water-soluble protective coating are also disclosed herein.

Abstract: A method for detecting a storage life of a pre-crosslinked material is provided. Tableting is performed on an unaged pre-crosslinked material to obtain crosslinked polyethylene. A crosslinking degree and a mechanical property of the crosslinked polyethylene are measured to obtain reference data. The pre-crosslinked material is heated to obtain a fast-aged pre-crosslinked material. The crosslinking degree and mechanical property of crosslinked polyethylene obtained from the fast-aged pre-crosslinked material are measured to obtain measurement results, which are compared with the reference data. If comparison results all fall within corresponding ranges, the time period of heating is increased by a step to repeat the above steps until the comparison results do not all fall within the corresponding ranges. A result obtained by subtracting the step from the time period of heating is converted into a time period of storage at the room temperature.

Abstract: A process and system for the conversion of a feedstock comprising C3-C5 light alkanes to a C5+ hydrocarbon product, for example, a BTX-rich hydrocarbon product, by performing the alkane activation (first-stage) and the oligomerization/aromatization (second-stage) in separate stages, which allows each conversion process to occur at optimal reaction conditions thus increasing the overall hydrocarbon product yield. The alkane activation or first-stage is operated at a higher temperature than the second-stage since light alkanes are much less reactive than light olefins. Since aromatization of olefins is more efficient at higher pressure, the second-stage is maintained at a higher pressure than the first-stage. Further, fixed-bed catalysts are used in each of the first-stage and the second-stage.

Abstract: Bispecific monoclonal antibodies and methods for treating cancer are set forth herein.

Abstract: The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.